SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease

by Ysios Capital

SpliceBio is pleased to announce the signing of an exclusive collaboration and licensing agreement with Spark Therapeutics to utilize SpliceBio’s proprietary Protein Splicing platform to develop a g...

Read more

SpliceBio, participada por Ysios y Asabys, recibe el premio a la 'Serie A del año' en los European Lifestars awards

by Ysios Capital

SpliceBio, compañía biotecnológica de terapia génica con sede en Barcelona basada en tecnología desarrollada en la Universidad de Princeton, ha recibido el galardón a la “Ronda de Inversión S...

Read more

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

by Ysios Capital

SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing. The fina...

Read more
Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

The Bigas Lab finds Notch self-inhibitio...

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

It has been found that the population of haematopoietic stem cells (HS...

Photos Stream